Extensively drug-resistant mycobacterium tuberculosis (Q49350): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Revision as of 19:43, 13 August 2026
Extensively drug-resistant tuberculous mycobacteria are resistant to at least four of the core anti-TB drugs. XDR-TB mycobacteria are resistant to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance, in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin).
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | MG52.02 |
||
| English | Extensively drug-resistant mycobacterium tuberculosis |
Extensively drug-resistant tuberculous mycobacteria are resistant to at least four of the core anti-TB drugs. XDR-TB mycobacteria are resistant to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance, in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin). |
Statements
CID11:MG52.02
0 references
dki-india-MG52.02
0 references
Concluído
0 references
13 August 2026
0 references
